(Q43782897)

26 November 2017

title

Prevalence of adverse events associated with potent antiretroviral treatment: Swiss HIV Cohort Study (English)

1 reference

26 November 2017

1

1 reference

26 November 2017

10

1 reference

26 November 2017

Swiss HIV Cohort Study

13

object named as

Swiss HIV Cohort Study

1 reference

26 November 2017

6

M Battegay

1 reference

26 November 2017

K Boubaker

2

1 reference

26 November 2017

B Ledergerber

3

1 reference

26 November 2017

E Bernasconi

4

1 reference

26 November 2017

H Furrer

5

1 reference

26 November 2017

B Hirschel

7

1 reference

26 November 2017

P Vernazza

8

1 reference

26 November 2017

P Francioli

9

1 reference

26 November 2017

M Flepp

11

1 reference

26 November 2017

A Telenti

12

1 reference

26 November 2017

language of work or name

English

0 references

publication date

1 October 2001

1 reference

26 November 2017

1 reference

26 November 2017

volume

358

1 reference

26 November 2017

issue

9290

1 reference

26 November 2017

page(s)

1322-1327

1 reference

Management of the adverse effects of antiretroviral therapy and medication adherence

26 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906413-3

7 January 2021

Toxicity of antiretroviral agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906413-3

7 January 2021

The case for more cautious, patient-focused antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906413-3

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906413-3

7 January 2021

Antibiotic induced fatigue.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906413-3

7 January 2021

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906413-3

7 January 2021

A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906413-3

7 January 2021

Stavudine: an update of its use in the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906413-3

7 January 2021

Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906413-3

7 January 2021

Zidovudine: five years later

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906413-3

7 January 2021

Hyperlactatemia and antiretroviral therapy: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906413-3

7 January 2021

2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906413-3

7 January 2021

The didanosine Expanded Access Program: safety analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906413-3

7 January 2021

HIV-protease inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2801%2906413-3

7 January 2021

10.1016/S0140-6736(01)06413-3

Identifiers

DOI

1 reference

26 November 2017

1 reference